Literature DB >> 10639408

Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.

N Mielcarek1, I Nordström, F D Menozzi, C Locht, J Holmgren.   

Abstract

Intranasal administration of live attenuated Bordetella pertussis, from which the pertussis toxin gene has been deleted, has previously been shown to give rise to high levels of serum immunoglobulin G (IgG) antibodies against both the protective antigen filamentous hemagglutinin (FHA) and heterologous antigens genetically fused to FHA. Here, we extend these results by demonstrating that anti-FHA IgA and IgG antibodies are also produced in the genital tract of mice, both in the vagina and in the uterus, after a single intranasal administration of B. pertussis. By comparing the immune responses induced after infection with wild-type virulent B. pertussis with that induced by infection with an attenuated pertussis toxin-deficient strain, we conclude that pertussis toxin produced by the virulent bacteria does not modify antibody production to FHA in the genital tract of B. pertussis-infected mice. The intranasal infection with either the attenuated or the virulent B. pertussis strain also led to the development of immunologic memory that could be efficiently boosted with purified FHA administered either intranasally or intravaginally to give rise to a significant increase in the levels of specific IgA and IgG produced locally in the genital tract, as well as of specific antibodies in the serum. These observations suggest that attenuated B. pertussis could be a promising vector for intranasal administration to induce antibody responses against antigens from sexually transmitted pathogens fused to FHA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639408      PMCID: PMC97167          DOI: 10.1128/IAI.68.2.485-491.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

2.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.

Authors:  M Ryan; L McCarthy; R Rappuoli; B P Mahon; K H Mills
Journal:  Int Immunol       Date:  1998-05       Impact factor: 4.823

4.  Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.

Authors:  E L Johansson; C Rask; M Fredriksson; K Eriksson; C Czerkinsky; J Holmgren
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.

Authors:  G Renauld-Mongénie; N Mielcarek; J Cornette; A M Schacht; A Capron; G Riveau; C Locht
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.

Authors:  N Mielcarek; G Riveau; F Remoué; R Antoine; A Capron; C Locht
Journal:  Nat Biotechnol       Date:  1998-05       Impact factor: 54.908

7.  Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit.

Authors:  M W Russell; Z Moldoveanu; P L White; G J Sibert; J Mestecky; M Michalek S
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

8.  Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge.

Authors:  S Pal; I Theodor; E M Peterson; L M de la Maza
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

9.  Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen.

Authors:  N Mielcarek; J Cornette; A M Schacht; R J Pierce; C Locht; A Capron; G Riveau
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

10.  Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus.

Authors:  W S Gallichan; K L Rosenthal
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

View more
  3 in total

1.  Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Authors:  Si Ying Ho; Shi Qian Chua; Damian G W Foo; Camille Locht; Vincent T Chow; Chit Laa Poh; Sylvie Alonso
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

2.  Differential expression of adhesion molecules and chemokines between nasal and small intestinal mucosae: implications for T- and sIgA+ B-lymphocyte recruitment.

Authors:  Dorothée Bourges; Claire Chevaleyre; CaiHong Wang; Mustapha Berri; XiaoMei Zhang; Laetitia Nicaise; François Meurens; Henri Salmon
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

3.  Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.

Authors:  Violaine Dubois; Camille Locht
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.